Cargando…
TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients
BACKGROUND: Chemotherapy is the preferred treatment in many types of cancer including lung cancer. However, most of patients resist chemotherapy resulting in disease progressive and recurrence. Titin (TTN) mutation is proved as a beneficial role in lung squamous carcinoma (LUSC), but the predictive...
Autores principales: | Xue, Dan, Lin, Hongguang, Lin, Lan, Wei, Qiongying, Yang, Sheng, Chen, Xiangqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798240/ https://www.ncbi.nlm.nih.gov/pubmed/35116455 http://dx.doi.org/10.21037/tcr-20-2568 |
Ejemplares similares
-
Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
por: Wang, Zhe, et al.
Publicado: (2021) -
Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
por: Zeng, Dejun, et al.
Publicado: (2021) -
Deciphering Prognostic Value of TTN and Its Correlation With Immune Infiltration in Lung Adenocarcinoma
por: Chen, Jianing, et al.
Publicado: (2022) -
Mutations in the TTN Gene are a Prognostic Factor for Patients with Lung Squamous Cell Carcinomas
por: Zou, Sheng, et al.
Publicado: (2022) -
Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)